Editing Cardiomyopathy (section)

==Treatment==
Treatment may include suggestion of lifestyle changes to better manage the condition. Treatment depends on the type of cardiomyopathy and condition of disease, but may include medication (conservative treatment) or iatrogenic/implanted [[artificial pacemaker|pacemakers]] for slow heart rates, [[Implantable cardioverter-defibrillator|defibrillators]] for those prone to fatal heart rhythms, [[ventricular assist device]]s (VADs) for severe heart failure, or [[catheter ablation]] for recurring dysrhythmias that cannot be eliminated by medication or mechanical cardioversion. The goal of treatment is often symptom relief, and some patients may eventually require a [[heart transplant]].<ref name=ref2/>

[[Acoramidis]] (Attruby) was approved for medical use in the United States in November 2024, to treat adults with cardiomyopathy of wild-type or variant (hereditary) transthyretin-mediated amyloidosis (ATTR-CM) to reduce death and hospitalization related to heart problems.<ref name="FDA 20241125">{{cite web | title=FDA approves drug for heart disorder caused by transthyretin-mediated | website=U.S. Food and Drug Administration | date=1 October 2024 | url=https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-heart-disorder-caused-transthyretin-mediated-amyloidosis | access-date=27 November 2024}} {{PD-notice}}</ref>